Geographic variation in drug safety: Potentially unsafe prescribing of medications and prescriber responsiveness to safety alerts

Journal of Managed Care Pharmacy

Volumn 16, Issue 3, 2010, Pages 196-205

  Feifer, Richard A ^a   James, Jason M ^a  

^a Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATENOLOL; CALCINEURIN INHIBITOR; CENTRAL STIMULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; MEDROXYPROGESTERONE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; PRESCRIPTION DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHY; MEDICAL DECISION MAKING; PHARMACIST; PHYSICIAN; PREGNANCY; PRESCRIPTION; TREATMENT DURATION; UNITED STATES; ADULT; CLINICAL PRACTICE; DECISION MAKING; HUMAN; MEDICATION ERROR; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; REMINDER SYSTEM; STANDARD; STATISTICS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DECISION MAKING; HUMANS; MEDICATION ERRORS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTION DRUGS; REMINDER SYSTEMS; UNITED STATES;

EID: 77952315374     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.3.196     Document Type: Article

References (40)

1. Institute of Medicine. Informing the Future: Critical Issues in Health, 4th ed. Washington, D.C.: National Academies Press; 2007. Available for free download at: http://www.nap.edu/catalog/12014.html. Accessed February 21, 2010.
2. IMS Health. 2008 U.S. sales and prescription information. Available at: http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 85f4a56216a10210VgnVCM100000ed152ca2RCRD&cpsextcurrchannel=1. Accessed February 21, 2010.
3. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures - 2009. Am J Health Syst Pharm. 2009;66(3):237-257
4. Institute of Medicine. Preventing Medication Errors. Quality Chasm Series. Washington, DC: National Academies Press; 2007. Available for purchase at: http://www.nap.edu/catalog.php?record-id=11623. Accessed February 21, 2010.
5. Patel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem? Pharmacotherapy. 2002;22(7):915-923 (Pubitemid 34743441)
6. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-1248
7. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136-47. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2000562/pdf/bcp0063-0136.pdf. Accessed February 9, 2010. (Pubitemid 46072098)
8. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-199
9. Center for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group. National health expenditures aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1960-2008. Available at: http://www.cms.hhs.gov/NationalHealthExpendData/ downloads/tables.pdf. Accessed February 21, 2010.
10. MacKinnon NJ, Hepler CD. Indicators of preventable drug-related morbidity in older adults 2. Use within a managed care organization. J Manag Care Pharm. 2003;9(2):134-141 Available at: http://www.amcp.org/data/jmcp/Research-134-141. pdf.
11. Curtiss FR. Effective integration of medical and pharmacy claims to better protect patient safety - a long road yet to travel. J Manag Care Pharm. 2007;13(5):429-430 Available at: http://www.amcp.org/data/jmcp/JMCPMaga- June%2007-p429-430.pdf.
12. Wennberg JE, Fisher ES, Goodman DC, Skinner JS. Tracking the Care of Patients with Severe Chronic Illness: The Dartmouth Atlas of Health Care 2008. Lebanon, NH: The Dartmouth Institute for Health Policy & Clinical Practice; 2008.
13. Bronner E, ed. Effective care: a Dartmouth Atlas Project topic brief. Unwarranted variation: the overuse, underuse, and misuse of care. January 15, 2007. Available at: http://www.dartmouthatlas.org/topics/effective-care.pdf. Accessed February 21, 2010.
14. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281(7):627-33. Available at: http://jama.ama-assn.org/cgi/ reprint/281/7/627. Accessed February 21, 2010.
15. Dombkowski KJ, Cabana MD, Cohn LM, Gebremariam A, Clark SJ. Geographic variation of asthma quality measures within and between health plans. Am J Manag Care. 2005;11(12):765-72. Available at: http://www.ajmc.com/media/pdf/AJMC- 05decDombkowski765.pdf. Accessed February 21, 2010. (Pubitemid 41790965)
16. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111(2):237-43. Available at: http://pediatrics.aappublications.org/cgi/reprint/111/2/237. Accessed February 21, 2010. (Pubitemid 36177138)
17. Zerzan JT, Morden NE, Soumerai S, et al. Trends in geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care. 2006;44(11):1005-1010
18. Curtis LH, Stoddard J, Radeva JI, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res. 2006;41(3 Pt 1);837-55. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1713206/pdf/hesr041-0837.pdf. Accessed February 21, 2010.
19. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-23. Available at: http://circ.ahajournals.org/ cgi/content/full/117/18/2407. Accessed February 21, 2010.
20. U.S. Food and Drug Administration. Communication about an ongoing safety review of stimulant medications in children with attention-deficit/hyperactivity disorder (ADHD). Last updated November 10, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm. Accessed February 21, 2010.
21. Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-53. Available at: http://pediatrics.aappublications.org/cgi/ content/full/122/2/451. Accessed February 21, 2010.
22. Cordarone (amiodarone HCl) tablets. Wyeth Pharmaceuticals Inc. August 2009. Available at: http://www.wyeth.com/content/showlabeling.asp?id=93. Accessed February 21, 2010.
23. U.S. Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Last updated March 3, 2010. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm. Accessed March 11, 2010.
24. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum. 2000;43(9):1905-1915
25. U.S. Food and Drug Administration. Pimecrolimus (marketed as Elidel cream) information. May 22, 2009. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153524.htm. Accessed February 21, 2010.
26. U.S. Food and Drug Administration. Tacrolimus (marketed as Protopic ointment) information. January 21, 2010. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107845.htm. Accessed February 21, 2010.
27. American College of Allergy, Asthma & Immunology/American Academy of Allergy, Asthma & Immunology. Report of the topical calcineurin inhibitor task force of the ACAAI and AAAAI. February 1, 2006. Available at: http://www.aaaai.org/members/academy-statements/practice-papers/ calcineurin-task-force.pdf. Accessed February 21, 2010.
28. U.S. Food and Drug Administration. Public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. January 20, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ucm053113.htm. Accessed February 21, 2010.
29. Cooper WO, Hernandez-Diaz S, Aborgast P, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51. Available at: http://content.nejm.org/cgi/reprint/354/23/ 2443.pdf. Accessed February 21, 2010. (Pubitemid 43855047)
30. Lopressor (metoprolol tartrate) tablets and injection. Novartis Pharmaceuticals Corp. March 2009. Available at: http://www.pharma.us.novartis. com/product/pi/pdf/lopressor.pdf. Accessed February 21, 2010.
31. Tenormin (atenolol) tablets. AstraZeneca Pharmaceuticals LP. April 2008. Available at: http://wwwl.astrazeneca-us.com/pi/tenormin.pdf. Accessed February 21, 2010.
32. Depo-Provera (medroxyprogesterone acetate) contraceptive injection. Pharmacia & Upjohn Company. May 2006. Available at: http://media.pfizer.com/ files/products/uspi-depo-provera-contraceptive.pdf. Accessed February 21, 2010.
33. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM. Depot medroxyprogesterone acetate and bone mineral density in adolescents - the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39(2):296-301. (Pubitemid 44062349)
34. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;112(3):727-730
35. Ambien (zolpidem tartrate) CIV tablets. Sanofi-Aventis US LLC. September 2009. Available at: http://products.sanofi-aventis.us/ambien/ambien.pdf. Accessed February 21, 2010.
36. U.S. Department of Health & Human Services. Health information privacy. Available at http://www.hhs.gov/ocr/privacy/hipaa/faq/disclosures/ index.html. Accessed February 21, 2010.
37. First DataBank. NDDF Plus module [database]. San Bruno, CA: First DataBank; 2009. Updated November 21, 2009. Available at: http://www. firstdatabank.com/Products/national-drug-data-file-NDDF.aspx. Accessed December 3, 2009.
38. Weinstein JN, Bronner KK, Morgan TS, and Wennberg JE. Trends and geographic variations in major surgery for degenerative diseases of the hip, knee, and spine. Health Aff (Millwood). 2004;Supple Web Exclusives:VAR81-89.
39. Kaiser Family Foundation. Health Status. State Health Facts website. Available at: http://www.statehealthfacts.org/comparecat.jsp?cat=2. Accessed February 21, 2009.
40. Clark RC, Maxwell SR, Kerr S, et al. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions. Drug Saf. 2007;30(4):357-366